Pyrilutamide (development code KX-826) is a nonsteroidal antiandrogen, specifically a selective high-affinity silent antagonist of the androgen receptor. It is being developed by Kintor Pharmaceutical of China for the treatment of male androgenetic alopecia.
Pyrilutamide appears to be a promising new topical treatment for hair loss. It works on a similar mechanism as oral DHT inhibitors such as finasteride and dutasteride, but it is less likely to cause side effects such as decreased libido or erectile dysfunction.
Buy pyrilutamide is a high-affinity silent androgen receptor antagonist currently in phase II clinical trials for androgenic alopecia in the US and China. It is being developed by Kintor Pharmaceutical. The company is also testing the drug for alopecia in female patients. The drug has a very good safety profile and demonstrated efficacy in phase I trials.
It’s an interesting compound and has a very strong mechanism of action against DHT, so it could be a useful alternative to finasteride and dutasteride for men with sensitive scalps or who experience side effects from these drugs. It’s also a very promising new development for women with alopecia who are looking for an alternative to RU58841.
PyriPure is a topical solution of 0.5% pyrilutamide in a propylene glycol and ethanol vehicle. It’s available in 30ml sample bottles or by bulk. The raw material for this product is >99% pure and is tested by a 3rd party lab before it’s made into a formulation for human use.
Pyrilutamide (development code KX-826) is a high-affinity silent antagonist of androgen receptors. The topical drug has been shown to have a strong impact on DHT function in various clinical trials and it has the potential to treat androgenic alopecia. It also has a lower risk of side effects than oral 5-alpha reductase inhibitors such as finasteride or RU58841.
The latest press release from Kintor Pharmaceuticals reveals that the first patients in a US phase 2 trial for males with AGA have been dosed. The randomized, double-blind, placebo-controlled clinical trial will observe changes in the non-vellus hair count over a six month period.
We are interested in hearing from people who have used buy pyrilutamide from MV Supplements and what their experiences have been like. We will keep you updated on further developments with this promising new product.
Pyrilutamide is a nonsteroidal anti-androgen that blocks testosterone and DHT from binding with the androgen receptor in the follicle. This prevents the conversion of testosterone to DHT and halts hair loss. The drug is an alternative to oral 5-alpha reductase inhibitors such as finasteride and dutasteride, which have the potential to cause side effects such as decreased libido and erectile dysfunction.
In a press release today Kintor Pharmaceuticals announced that the first patient has been dosed in a phase 3 trial for pyrilutamide in male androgenic alopecia (AGA). The double-blinded, placebo-controlled clinical trial will measure changes in target area hair count over 6 months of treatment.
Kintor Pharmaceuticals is a biotechnology company with a focus on developing innovative treatments for AR-related diseases. Their latest development, pyrilutamide, is an androgen receptor antagonist that has shown promising early efficacy in a phase II trial for AGA. For more information on the global market for this drug, buy GlobalData’s Pyrilutamide PTSR and LoA report.
Pyrilutamide powder can be stored in dry, dark area away from sunlight and at 0 – 4 C for long term storage. It can be dissolved in propylene glycol and ethanol vehicle, but should not be mixed with water due to the nitrile group which will be hydrolyzed in water.
All our stocks of Pyrilutamide are lab tested and confirmed >99% pure by a 3rd party laboratory. This product is for laboratory developmental research USE ONLY and not for human consumption.
KX-826, also known as Pyri or pyrlutamide, is an antiandrogen in the development stage by Kintor Pharmaceuticals for androgenic alopecia (AGA). It is a synthetic, nonsteroidal, nitro-aromatic compound that blocks testosterone and DHT from binding to the androgen receptor in the hair follicle.
This is an early-stage drug which is in phase II clinical trials. GlobalData’s proprietary data and analytics are used to create drug-specific PTSR and LoA reports based on 18 years of historical drug development and commercialization data.